Table 1.
Current Genital Ulcer Disease Prevalence Over 24 Months Among Men and Women, Stratified by Study Arm and Duration of Antiretroviral Therapy (ART)
| Visits, Proportion (%)a |
Prevalence Rate Ratio (95% CI) |
||||
|---|---|---|---|---|---|
| ART Duration | Acyclovir Arm | Placebo Arm | Total | Unadjusted | Adjustedb |
| None received | 29/4529 (0.6) | 92/4367 (2.1) | 121/8896 (1.4) | 1.00 (reference) | 1.00 (reference) |
| 0–3 mo post | 4/212 (1.9) | 9/252 (3.6) | 13/464 (2.8) | 1.98 (1.05–3.75) | 1.94 (1.04–3.62) |
| 4–6 mo post | 5/107 (4.7) | 3/151 (2.0) | 8/258 (3.1) | 2.08 (0.99–4.38) | 1.99 (.94–4.22) |
| >6 mo post | 2/238 (0.8) | 4/280 (1.4) | 6/518 (1.2) | 0.81 (0.35–1.87) | 0.80 (.35–1.80) |
Abbreviations: CI, confidence interval; HSV-2, herpes simplex virus 2.
a Data are no. of visits during which HSV-2 shedding was detected/no. of visits HSV-2 shedding was evaluated (%), unless otherwise indicated.
b Analyses were adjusted for sex and trial arm (acyclovir or placebo).